About us

Our History

1988
FARMAPROJECTS, S.A.U. was founded in 1988 as a service company within the pharmaceutical industry, specialized in drug registration
1995
In 1995, Farmaprojects undertook the development of generic pharmaceutical specialties for third companies and since then it has developed its activity to meet the needs in this sector of both national and foreign pharmaceutical companies
Click Here
1998
In 1998, the business took a turn in its activity, ceasing to work for third parties and starting to develop its own products so that they could be registered in all European Community countries and in the rest of the world
Click Here
2000
In the year 2000, Farmaprojects obtained authorization from the record-holder pharmaceutical laboratory
Click Here
2001
In 2001, the business created its own analytical development and quality control laboratory
Click Here
2002
In 2002, Farmaprojects obtained the partial manufacturer pharmaceutical laboratory authorization (Quality Control)
Click Here
2003
In 2003, the company obtained authorization as a marketing laboratory and established a representative office in Mumbai (India)
Click Here
2005
In 2005, the procedures for the manufacture of finished products began in India and an office was established in Shanghai (China)
Click Here
2006
In 2006, the GMP (Good Manufacturing Practice) certificate was obtained
Click Here
2007
In 2007, a change of corporate image was carried out, creating a new image that would transmit the essence and identity of the company in accordance with its values
Click Here
2008
In 2008, the business was focused on from the central offices in L’Hospitalet de Llobregat - Barcelona (Spain) and India
Click Here
2009
In 2009, Finsiècle acquired 100% of the shares of Farmaprojects, of which up until then had 50%. With this acquisition, new business synergies were generated with the Polpharma Group
Click Here
2010
In 2010, the company worked on the integration of teams and functions with the Polpharma Group, taking advantage of the synergies between the companies
Click Here
2011
In 2011, Farmaprojects began a new chapter in its business. The supply of product for public auction (Tenders) starts in the German market
Click Here
2014
In 2014, Farmaprojects established itself as a strategic partner of the Polpharma Group for the commercialization of its products and services worldwide within the Business to Business segment
Click Here
2017
In 2017, Farmaprojects established its headquarters in Provença Street in Barcelona
Click Here
2019/2020
In 2019/2020, Farmaprojects begins the project to expand its laboratory services at the Parc Cientific in Barcelona
Click Here
Previous
Next

Mission & Vision

Mission

We are committed to the success of our partners in the Pharma industry by offering tailor made solutions and leading edge expertise with a human touch to make our common growth dreams come true.

We are committed to the success of our partners in the Pharma industry by offering tailor made solutions and leading edge expertise with a human touch to make our common growth dreams come true.

To be the preferred business partner for every pharma company in the industry by leading a new generation of services in the world of generics.

To be the preferred business partner for every pharma company in the industry by leading a new generation of services in the world of generics.

Vision

Strategic alliance

With over 3 decades of experience in out-licensing model and regulatory affairs, Farmaprojects joined forces with one of the biggest Pharma players in Europe in order to provide full service to their business partners. Farmaprojects B2B pharma expertise round off with Polpharma’s solid manufacturing, product development and commercialization expertise.

We offer

  • Attractive portfolio
  • Customer centric approach
  • Sustained production strategy
  • Market driven
  • Customized commercial conditions

Focus on the newest Cardiology trends, developing mono & combo products

Wide Oral Antidiabetics portfolio (Combinations & Plain)

Anti-obesity main Molecule (Orlistat)

Other key therapeutic groups: Antithrombotic, Nervous System and Respiratory drugs, among others

Lyophilized portfolio

Multidisciplinary Team Support

Combined efforts with Polpharma’s volumes, guarantees supply continuity

Technical team fully dedicated to secure on-time launches

2 API suppliers to reduce risks

Planning & Production Team

Dossier adjustment to different non-EU market requirements

Products tested for Zone IV territories

Flexibility of Business Model for selected markets

Early launch possibility (FTO)

Competitive COGS based on economyof scales

API manufactured internally

Dedicated Customer Service

Attractive portfolio

Focus on the newest Cardiology trends, developing mono & combo products

Wide Oral Antidiabetics portfolio (Combinations & Plain)

Anti-obesity main Molecule (Orlistat)

Other key therapeutic groups: Antithrombotic, Nervous System and Respiratory drugs, among others

Lyophilized portfolio

Customer centric approach

Multidisciplinary Team Support

Sustained production strategy

Combined efforts with Polpharma’s volumes, guarantees supply continuity

Technical team fully dedicated to secure on-time launches

2 API suppliers to reduce risks

Planning & Production Team

Market driven

Dossier adjustment to different non-EU market requirements

Products tested for Zone IV territories

Flexibility of Business Model for selected markets

Early launch possibility (FTO)

Customized commercial

Competitive COGS based on economyof scales

API manufactured internally

Dedicated Customer Service

Our presence in the world

Farmaprojects has a global approach, for which we are constantly working to expand our business to other markets, adapting to the uniqueness of each territory.